Complete Genomics Launches Cancer Grant Program

Complete Genomics Launches Cancer Grant Program

Selected Researchers Will Receive Complete Human Genome Sequencing of Eight Genomes 

MOUNTAIN VIEW, Calif., Jun 29, 2011 (GlobeNewswire via COMTEX) -- Complete Genomics Inc. /quotes/zigman/1318953/quotes/nls/gnom GNOM -0.65% , a complete human genome sequencing company, today announced that it is introducing a new cancer grant program. Winning research applications will receive complete human genome sequencing of eight genomes -- four tumor/normal pairs. Four winning entries will be chosen: two each from the United States and Europe.

Complete Genomics is accepting grant applications for cancer-specific research projects using its complete human genome sequencing service from now until July 29, 2011. Applications will be evaluated by an internal panel of scientific experts at Complete Genomics. Winners will be notified by Aug. 12 and will be required to submit their samples by Sept. 16. In addition, all applicants will be automatically eligible for a discount on their next complete human genome sequencing project.

"We designed this grant program to recognize and reward those scientists who are developing innovative cancer research projects," said Dr. Clifford Reid, chairman, president and CEO of Complete Genomics. "We are delighted to have the opportunity to provide pioneering scientists with complete human genome sequencing and research-ready data that they can immediately use to gain insights into the characterization and possible treatment of various cancers."

For more information about the grant program or to submit an application, please visit at http://www.completegenomics.com/news-events/grant-program/ .

About Complete Genomics

Complete Genomics is a complete human genome sequencing company that has developed and commercialized an innovative DNA sequencing platform. The Complete Genomics Analysis Platform (CGA(TM) Platform) combines Complete Genomics' proprietary human genome sequencing technology with our advanced informatics and data management software. We offer this solution as an innovative, end-to-end, outsourced service, CGA(TM) Service, and provide customers with data that is immediately ready to be used for genome-based research. Additional information can be found at http://www.completegenomics.com .

The Complete Genomics logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8216

Forward-Looking Statements

Certain statements in this press release, including statements relating to the ability of scientists to use the genome sequencing data that we provide to them to immediately gain insights into the characterization and possible treatment of various cancers are forward-looking statements that are subject to risks and uncertainties. Readers are cautioned that these forward-looking statements are based on management's current expectations, and actual results may differ materially from those projected. The following factors, without limitation, could cause actual results to differ materially from those in the forward-looking statements: the ability of scientists to successfully analyze the genomic data we provide; and the ability of researchers to convert genomic data into medically valuable information. More information on potential factors that could affect the usefulness of the genomic data that we provide to our customers is included in our Securities and Exchange Commission filings and reports, including the risks identified under the section captioned "Risk Factors" in our Registration Statement on Form S-1 filed on May 18, 2011. We disclaim any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events or otherwise.

Suggested Articles

Smaller biotechs are continuing their biopharma hiring spree as two startups nab some big names for their aspiring cancer drug research.

In a 7-2 vote, an FDA panel backed Aimmune’s peanut allergy treatment for approval. It desensitizes patients with increasing doses of peanut protein.

In a phase 1 trial of Atara's T-cell therapy for MS, patients who received the highest of the two doses reported showed an improvement in symptoms.